Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.

Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PA

Open source

DOI
10.1016/j.clml.2023.09.005
Published
2024 Feb
Container
Clinical lymphoma, myeloma & leukemia
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clml.2023.09.005,
  title = {Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.},
  author = {Rojek AE and Kline JP and Feinberg N and Appelbaum DE and Pu Y and Derman BA and Jakubowiak A and Kosuri S and Liu H and Nawas MT and Smith SM and Bishop MR and Riedell PA},
  year = {2024},
  journal = {Clinical lymphoma, myeloma \& leukemia},
  doi = {10.1016/j.clml.2023.09.005},
  url = {https://doi.org/10.1016/j.clml.2023.09.005}
}

RIS

TY  - JOUR
TI  - Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
AU  - Rojek AE
AU  - Kline JP
AU  - Feinberg N
AU  - Appelbaum DE
AU  - Pu Y
AU  - Derman BA
AU  - Jakubowiak A
AU  - Kosuri S
AU  - Liu H
AU  - Nawas MT
AU  - Smith SM
AU  - Bishop MR
AU  - Riedell PA
PY  - 2024
JO  - Clinical lymphoma, myeloma & leukemia
DO  - 10.1016/j.clml.2023.09.005
UR  - https://doi.org/10.1016/j.clml.2023.09.005
ER  - 

APA

AE, R., JP, K., N, F., DE, A., Y, P., BA, D., A, J., S, K., H, L., MT, N., SM, S., MR, B., & PA, R. (2024). Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2023.09.005

Source records